Sources Sought Notice – Q– Immunohistochemistry Lab Consultative Services VA Maine
Notice Type: Sources Sought Notice
Posted Date:
Office Address:
Subject: Q-- Immunohistochemistry Lab Consultative Services VA
Classification Code: Q - Medical services
Solicitation Number: VA24116Q0196
Contact: Valerie DeAngelisContracting Specialist 401-459-4760 x1594 mailto:[email protected]
Description:
Providence VAMC
Sources Sought Notice - Immunohistochemistry Consultation Services
This is a Sources Sought notice and not a request for quotes. This request is solely for the purpose of conducting market research to enhance VHA's understanding of your company's offered services and capabilities. The Government will not pay any costs for responses submitted in response to this Sources Sought.
This Sources Sought notice provides an opportunity for respondents to submit their notice of ability, and their available products in response to the requirement described below. Vendors are being invited to submit information relative to their potential of fulfilling the requirement below, in the form of a capability response that addresses the specific requirement identified in this Sources Sought.
The
GENERAL REQUIREMENTS
The contractor shall provide Immunohistochemistry Consultation services, to include courier transportation of these specimens. Contractor shall provide professional and technical services to include materials, supplies, equipment and qualified supervision specified herein. All Immunohistochemistry consultation services shall be performed at the Contractor's facility. Contractor must accept specimens Monday through Saturday
1. Perform consultation and technical services entirely upon their premises.
for the following:
" Diagnostic Immunohistochemistry markers- technical component only
" Immunohistochemistry morphometric analysis, tumor immunohistochemistry
quantitative or semi quantitative- technical component only
" Immunohistochemistry markers- technical component only specific for colorectal
Cancer
" Professional consultation for select cases
2. Be responsible for the pick-up and transportation of specimens to the contractor's laboratory. The contractor shall be responsible for transporting in such a manner as to ensure the integrity of the specimen. The contractor shall supply special preservatives as required for specimen preservation and packing material capable of maintaining temperature requirements for specimens until they reach the Contractor's laboratory under the terms of this agreement. The Contractor shall provide return transportation of specimens/slides to the
3. Notwithstanding anything to the contrary in this PWS or otherwise, the CONTRACTOR LABORATORY shall not release patient's records that include test results to any person other than the ordering healthcare provider or designee. All member records shall be treated as confidential so as to comply with all state and federal laws regarding the confidentiality of patient's records. This provision shall survive termination of the Contract.
4. Certify and ensure that all employees, officers, or agents do not use Protected Health Information received from any VAMC site that would constitute a violation of any applicable provision in standards set forth in the Health Insurance Portability and Accountability Act (HIPAA).
5. Contractor's Medical Staff will be available to all VAMCs as a resource for education about disease conditions and testing options.
6. Telephone any abnormal or unexpected results to the Chief of Pathology and Laboratory Medicine Service at the
7. Hard copy results and consultative reports shall provide individual patient-chartable test result reports meeting Clinical Laboratory Improvement Act of 1988 (CLIA) requirements and must be electronically transmitted to each Point of contact (POC) for local printing. Printed reports will include:
" The name and address of the contract laboratory where each test was performed
" The specimen accession number of the contract laboratory
" The name of the contract Laboratory Director or Medical Director
" The date and time a specimen was collected at the VAMC
" The date and time a specimen was received by the contractor laboratory and completed
" The pathologist or technologist signature as appropriate
" A phone number to contact the
"
" The patient's name
" The patient's age or date of birth
" The patient's sex
"
" The Contractor's report date and time
" The test name
" The test result(s)
" The unit of measurement for quantitative tests
" The normal or expected range (reference range adjusted for age, sex, or race when appropriate).
" The report status (i.e., final or interim)
" Other interpretive information appropriate for the test(s)
" CPT code
8. In cases of malfunction of the Contractor-supplied electronic reporting method lasting more than 24 hours, the Contractor shall, without additional charge, provide express overnight shipping or courier delivery of printed reports to each POC until the automated information system is properly functioning.
9. Provide running history for lab results by patient when requested.
10. Provide appropriate requisition forms and unique supplies needed for specialized collection of samples at no additional charge.
11. Pick up patient specimens no earlier than
12. Carry out its functions hereunder in full compliance with all local, state, and Federal laws or regulations.
13. If lab results are not performed within 2 days, it is up to the facility point of contact to track the late results and track specific instances in the Quality Assurance Worksheet for submission to the
14. Test result and/or report corrections shall be made with corrected reports sent to the
15. The Contractor shall notify the originating laboratory by telephone of specimens not
processed due to unacceptability (e.g. volume, specimen container, identification, loss
of specimen, etc.).
16. The contractor shall, upon completion of testing and reporting, return all specimens.
17. The facility POC will request replenishment of supplies from the contractor on an as
needed basis.
18. Must provide a current Laboratory Manual containing the following information:
" Department hours of operation
" Accreditation
" Technical Staff
" Service Departments (Method of contacting, phone numbers, hours of availability)
" Quality Assurance Information such as, but not limited, to specimen labeling and rejection criteria
" Billing Procedures & fee schedules for services provided
" Procedures and criteria for phoning reports and other important information
" Report forms
19. Must maintain the minimum acceptable service, reporting systems, and quality control as specified herein. Immediate (within 24 hours) notification must be given to
20. Must assign a specific local account representative.
21. Must advise COR of any changes in methodology, procedure or reference ranges.
22. Must provide telephone number(s) and contact person(s) to be used by the
LICENSING AND ACCREDITATION:
1. Shall have all licenses, permits, accreditation certificates required by Federal law and State law in the state of
2. Shall be accredited by the
3. Medical Director must have suitable qualifications and experience to direct a laboratory providing consultation services under this contract according to
4. Contractor Personnel assigned by the Contractor to perform the services covered by this contract shall be eligible to provide the services of this contract and licensed in a State, Territory, or Commonwealth of
5. Must submit a copy of the professional certification and/or licensure of the Laboratory Director and/or Medical Director with the proposal.
6. Must comply with the regulatory requirements of Health and
7. Must notify the Contracting Officer immediately, in writing, upon its loss (of any of its subcontractors) of any required certification, accreditation, or licensure.
QUALITY CONTROL:
The contractor must operate a successful quality control program as required by CAP. Services are to be performed in accordance with this PWS. The quality control program must include procedures to identify, prevent, and ensure non-recurrence of defective services. The contractor's quality control program is the means by which the contractor laboratory assures that work complies with the requirement of the contract. A quality assurance surveillance program will be submitted as part of an offer and put into place upon final contract award. After acceptance of the quality assurance plan the contractor shall receive the contracting officer's acceptance in writing of any proposed change to this Quality Control system.
QUALITY ASSURANCE:
The Contractor shall comply with all applicable
RESPONSE COMMITMENT
I. NOTES:
A. All questions, comments or concerns should be directed to [email protected]
B. Submittals furnished will not be returned to the sender. No debriefs will be conducted. Eligibility in participating in a future acquisition does not depend upon a response to this notice.
C. Proprietary information is neither requested nor desired. If such information is submitted, it must clearly be marked "proprietary" on every sheet containing such information, and the proprietary information must be segregated to the maximum extent practicable from other portions of the response (e.g., use an attachment or exhibit).
II. TIMELINE :
A. This request will close on stated date within the FBO site.
III. Requested information:
Interested parties shall provide the following information in addition to your capability response:
A. Format:
1. MS Word or pdf format (please ensure email is under 5 mb)
2. Page limit - 2-4 pages (please make the response as brief and concise as possible)
3. Company name and Sources Sought number listed on each page
B. Specifics:
1. In your response, please provide the following information based on the requirement.
a. Your company's capability of fulfilling this requirement as it is described.
2. Please also provide name of company, company address, a contact person's name, telephone number, fax number and email address.
3. DUNS number, and indicate if actively registered on System for award management (SAM)
4. Contractual vehicles the company holds, such as NAC or GSA schedules.
5. Socio-economic Status & NAICS Code: State the size of your company [e.g., 8(a) (including graduation date), HUBZone-certified small business, Service-Disabled Veteran-Owned small business, small business, large business, etc.].
Notes:
1. This Sources Sought is for planning purposes only, and does not constitute a commitment, implied or otherwise, that a procurement action will follow. The
2. The content of any responses to this notice may be reflected in any subsequent solicitation, except for content marked or designated as business confidential or proprietary which will be fully protected from release outside the government.
Contract Specialist
Email: [email protected]
Test Menu
Item Description Annual Est. Quantity
1 ALPHA 1-ANTITRYPSIN, IHC W/O INTERPRETATION_88342-TC 0-1
2 ALPHA-FETOPROTEIN, IHC W/O INTERP_88342-TC 4
3 AMYLOID A,IHC W/O INTERP _88342-TC 1
4 ANAPLASTIC LYMPHOMA
5 ANDROGEN RECEPTOR, IHC W/O INTERPRETATION_88342-TC 0-1
6 ANNEXIN, IHC W/O INTERP _88342-TC 0-1
7 B72.3, IHC W/O INTERPRETA _88342-TC 0-1
8 B-CELL RECEPTOR IGH GENE REARRANGEMENT, PCR_81261, 84999 0-1
9 BCL-2,IHC W/O INTERPRETA _88342-TC 9
10 BCL-6, IHC W/O INTERPRETA _88342-TC 9
11 BETA CHORIONIC GONADOTRO PIN, IHC W/O INTERP_88342 1
12 BEREP4, IHC W/O INTERP _88342-TC 3
13 BOB1, IHC W/O INTERP _88342-TC 2
14 BRAF MUTATION ANALYSIS _81210 0-1
15 CA125, IHC W/O INTERP _88342-TC 0-1
16 CA19-9, IHC W/O INTERP _88342-TC 6
17 CD 10, IHC W/O INTERP _88342-TC 38
18 CD 117-CKIT, IHC W/INTERP _88342 0-1
19 CD 117-CKIT, IHC W/O INTERPRETATION_88342-TC 9
20 CD 1A, IHC W/O INTERP _88342-TC 0-1
21 CD138, IHC W/O INTERP _88342-TC 13
22 CD15, IHC W/O INTERPRETA _88342-TC 5
23 CD163,IHC W/O INTERP _88342-TC 5
24 CD2, IHC W/O INTERPRETATN _88342-TC 0-1
25 CD20, IHC W/O INTERPRETA _88342-TC 42
26 CD21, IHC W/O INTERP _88342-TC 2
27 CD23, IHC W/O INTERPRETA. _88342-TC 3
28 CD3, IHC W/O INTERPRETA _88342-TC 40
29 CD30, IHC W/O INTERPRETAT _88342-TC 11
30 CD31, IHC W/O INTERP _88342-TC 0-1
31 CD34, IHC W/O INTERP _88342-TC 25
32 CD38, IHC W/O INTERP _88342-TC 0-1
33 CD4, IHC W/O INTERPRETATI _88342-TC 0-1
34 CD43, IHC W/O INTERP _88342-TC 0-1
35 CD44, IHC W/O INTERP _88342-TC 1
36 CD45, IHC W/O INTERP _88342-TC 19
37 CD45RO (UCHL-1), IHC W/O INTERPRETATION_88342-TC 0-1
38 CD5, IHC W/O INTERP _88342-TC 9
39 CD56, IHC W/O INTERPRETAT _88342-TC 15
40 CD57, IHC W/O INTERPRETA. _88342-TC 1
41 CD61, IHC W/O INTERP _88342-TC 8
42 CD68, IHC W/O INTERP _88342-TC 1
43 CD7, IHC W/O INTERP _88342-TC 0-1
44 CD71, IHC W/0 INTERP _88342-TC 0-1
45 CD8, IHC W/O INTERP _88342-TC 0-1
46 CD99,IHC W/O INTERPRETA. _88342-TC 2
47 CDX2,IHC W/O INTERP _88342-TC 16
48 CEA, MONOCLONAL IHC W/O INTERP_88342-TC 0-1
49 CEA, POLYCLONAL, IHC W/O _88342-TC 11
50 CEBPA MUTATION ANALYSIS, EXTRACTED DNA_81403-90 0-1
51 CHROMOGRANIN, IHC W/O INT _88342-TC 19
52 CK14, IHC W/O INTERP _88342-TC 0-1
53 C-KIT MUTATION ANALYSIS, CELL-BASED_81404-90 0-1
54 CLARETININ,IHC W/O INTERP _88342-TC 7
55 COLORECTAL CANCER MUT PANEL_81210, 81275, 81404 0-1
56 COPPER, LIVER TISSUE _82525-90 0-1
57 CYCLIN D1 (BCL-1), IHC W/O INTERPRETATION_88342-TC 12
58 CYTOKERATIN 19, IHC W/O INTERPRETATION_88342-TC 4
59 CYTOKERATIN 20, IHC W/O INTERP_88342-TC 44
60 CYTOKERATIN 5/6, IHC W/O INTERPRETATION_88342-TC 37
61 CYTOKERATIN 7, IHC W/O IN _88342-TC 48
62 CYTOKERATIN 8 & 18(CAM5.2 IHC W/O INTERP_88342-TC 9
63 CYTOKERATIN AE1/AE3, IHC W/O INTERPRETATION_88342-TC 28
64 CYTOMEGALOVIRUS, IHC W/O INTERP_88342-TC 1
65 D2-40, IHC W/O INTERP _88342-TC 3
66 DBA44 HAIRY CELL IHC W/O INTERP_88342 1
67 DESMIN,IHC W/O INTERPRETA TION_88342-TC 4
68 DOG1, IHC W/O INTERP _88342-TC 0-1
69 E-CADHERIN, IHC W/O INTER _88342-TC 7
70 EML4-ALK GENE FUSION, PCR _81401-90 0-1
71 EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS _81235 0-1
72
73 EPSTEIN BARR VIRUS (EBV) ISH, WITHOUT INTERP_88365-TC 7
74 ER/PR, PARAFFIN BLOCK _88360 3
75 ESTROGEN RECEPTOR (ER) IHC, W/O INTERP_88360-TC 3
76 FACTOR 13A, IHC W/O INTER _88342-TC 9
77 GLIAL FIBRILLARY ACIDIC PROTEIN, IHC W/O INTERP_88342-TC 1
78 GLYCOPHORIN A, IHC W/O INTERP_88342-TC 11
79 GLYPICAN 3,IHC W/O INTERP _88342-TC 0-1
80 GRANZYME B, IHC W/O INTER _88342-TC 0-1
81 GROSS CYSTIC DISEASE FLUD 15, IHC W/O INTERP_88342-TC 1
82 HELICOBACTER PYLORI, IHC W/O INTERP_88342-TC 29
83 HEPATITIS B CORE, IHC W/O INTERPRETATION_88342-TC 0-1
84 HEPATITIS B SURFACE ANTIGEN,IHC W/O INTERPRET_88342-TC 0-1
85 HEPPAR-1, IHC W/O INTERPR _88342-TC 8
86 HER2 (HERCEPTEST[R]) IHC WITH REFLEX TO FISH_88360 7
87 HER2 (HERCEPTEST-TM) IHC, W/INTERPRETATION_88360 3
88 HER2 (HERCEPTEST-TM), IHC PARAFFIN BLOCK W/O INTERP_88360-TC 0-1
89 HERPES SIMPLEX VIRUS 2 IHC,W/O INT (DEL 3/9/15)_88342-TC 0-1
90 HERPES SIMPLEX VIRUS TYPE 1 AND 2, IHC W/O INTERP_88342-TC 0-1
91 HHF35 MUSCLE ACTIN, IHC W/O INTERP_88342-TC 0-1
92 HMB45, IHC W/O INTERPRETA _88342-TC 13
93 HPV ISH LOW/HIGH RISK W/INTERP._88364-90, 88365-90 3
94 HSV 1, IHC W/O INTERP (DELETED 3/9/15)_88342-TC 0-1
95 IGA, IHC W/O INTERP _88342-TC 0-1
96 IGG4. IHC W/O INTERP. _88342-TC 0-1
97 IMMUNOHISTOCHEMISTRY W/IN TERPRETATION_88342 0-1
98 IMMUNOHISTOCHEMISTRY W/O INTERPREATION_88342-TC 16
99 INHIBIN, IHC W/O INTERP _88342-TC 3
100 INI-1,IHC W/O INTERP _88342-TC 0-1
101 IRON-LIVER TISSUE _83540-90 0-1
102 KAPPA/LAMBDA LIGHT CHAIN ISH WITH INTERP_88364, 88365 0-1
103 KAPPA/LAMBDA LIGHT CHAIN, ISH W/O INTERP_88365-TC, 88366-TC 9
104 KI67, IHC W/O INTERP _88342-TC 9
105 KI-67/MART-1, IHC W/O INTERPRETATION_88342-TC 0-1
106 KRAS MUTATION ANALYSIS _81275 0-1
107 LAMBDA, IHC W/O INTERP _88342-TC 0-1
108 LUNG CANCER MUTATION PNL (EGFR,KRAS,ALK)_81235, 81275, 88271, 88274 5
109 LYNCH SYNDROME TUMOR PANEL, IHC W/O INTERP._88341-TC, 88342-TC 0-1
110 LYSOZYME, IHC W/O INTERP _88342-TC 0-1
111 MA903 CYTOKERATIN 34BE12 IHC W/O INTERP_88342-TC 1
112 MAMMAGLOBIN,IHC W/O INTE RP_88342-TC 0-1
113 MANTLE CELL LYMPHOMA BCL-1/JH_81401-90 0-1
114 MAST CELL TRYPTASE, W/O INTERP_88342-TC 0-1
115 MELAN-A, IHC W/O INTERPRE _88342-TC 0-1
116 MELANOMA ANTIGEN RECOG BY
117 MELANOMA, BRAF V600 MUTATION, COBAS_81210 0-1
118 MICROSATELLITE INSTABILIT _81301-90 0-1
119 MLH1, IHC W/O INTERP _88342-TC 0-1
120 MOC-31,IHC W/O INTERPRETA TION_88342-TC 1
121 MSH2,IHC W/O INTERP _88342-TC 0-1
122 MSH6, IHC W/O INTERP _88342-TC 0-1
123 MUM1, IHC W/O INTERP _88342-TC 3
124 MYD88, MUTATION ANALYSIS _81479 0-1
125 MYELOPEROXIDASE, IHC W/O INTERP_88342-TC 12
126 MYO D1, IHC W/O INTERPRET _88342-TC 0-1
127 MYOGENIN, IHC W/O INTERPR _88342-TC 0-1
128 NAPSIN A, IHC W/O INTERP _88342-TC 0-1
129 NEUROFILAMENT PROTEIN,IHC W/O INTERPRETATION_88342-TC 5
130 NEURON-SPECIFIC ENOLASE IHC W/O INTERPRETATION_88342-TC 8
131 NPM(EXON 12) MUT ANALYSIS CELL-BASED_81310-90 0-1
132 NRAS MUTATION ANALYSIS _81404 0-1
133 P16, IHC W/INTERP _88342 0-1
134 P16, IHC W/O INTERPRETA TION_88342-TC 1
135 P504S,IHC W/O INTERPRETA _88342-TC 3
136 P53, IHC W/O INTERPRETATI _88342-TC 7
137 P63, IHC W/O INTERP _88342-TC 29
138 PAX2,IHC W/O INTERP _88342-TC 7
139 PAX-5, IHC W/O INTERP _88342-TC 4
140 PAX8,IHC W/O INTERP _88342-TC 4
141 PD-1, IHC WITH INTERP. _88342 3
142 PLACENTAL ALAKALINE PHOS. IHC, W/O INTERPRETATION_88342-TC 1
143 PMS2, IHC W/O INTERP _88342-TC 0-1
144 PROGESTERONE RECEPTOR IHC W/O INTERPRETATION_88360-TC 3
145 PROSTATE TRIPLE STAIN,IHC W/O INTERPRETATION_88344-TC 126
146 PROSTATIC ACD PHOSPHATASE IHC W/O INTERPRETATION_88342-TC 4
147 PROSTEIN, IHC W/O INTERPRETATION_88342-TC 0-1
148 PSA, IHC W/O INTERPRETA. _88342-TC 7
149 RENAL CELL CARCIN W/O INT _88342-TC 15
150 S-100,MONO,IHC W/O INTERP _88342-TC 0-1
151 S-100,PLOY,IHC W/O INTERP _88342-TC 19
152 SMOOTH MUSCLE ACTIN W/O INTERPRETATION_88342-TC 13
153 SPECIAL STAIN CHEM COMPONENT_88313 1
154 SPECIAL STAIN MICRO-ORGANISMS_88312 0-1
155 SPECIAL STAIN MISCELLANEOUS_88313 27
156 SPECIAL STAIN-ENZYMES _88319 1
157 SYNAPTOPHYSIN, IHC W/O IN TERPRETATION_88342-TC 23
158 T-CELL RECEPTOR (TCR) BETA GENE REARRANGEMENT_81340, 84999 0-1
159 T-CELL RECEPTOR (TCR) GAMMA GENE REARRANGE, PCR_81342, 84999 0-1
160 TERMINAL DEOXYNUCLEIC TRANSFERASE, IHC W/O INTE_88342-TC 0-1
161 THROMBOMUDULIN,IHC W/O IN TERP_88342-TC 0-1
162 THYROGLOBULIN, IHC W/O IN _88342-TC 0-1
163 THYROID CANCER MUTATION PANEL_81445 0-1
164 THYROID TRANSCRIPTION FAC -1, IHC W/O INTERPRETATIO_88342-TC 46
165 TIA1,IHC W/O INTERP _88342-TC 0-1
166 UROPLAKIN,IHC W/O INTERP _88342-TC 0-1
167 VILLIN,IHC W/O INTERP _88342-TC 1
168 VIMENTIN, IHC W/O INTERPR _88342-TC 16
169 WILMS' TUMOR-1, IHC W/O INTERPRETATION_88342-TC 0-1
170 Professional Consultation 88321 0-1
Link/URL: https://www.fbo.gov/spg/VA/PrVMAC650/PrVAMC650/VA24116Q0196/listing.html
Advisor News
- Embracing a family-centric approach to financial planning
- Family communication: Financial planning’s growing blind spot
- Americans aren’t turning retirement plans into action, LIMRA finds
- Ashley Hinson ‘death tax’ story collides with truth
- How advisors can prepare clients for an uncertain retirement landscape
More Advisor NewsAnnuity News
- Investigation finds deceptive sales, churning of annuities targeting postal workers
- Corebridge annuity sales slip ahead of Equitable marriage
- California teachers settle class-action lawsuit over in-plan annuity fees
- Jackson Financial CEO caps 40-year career with blockbuster Q2
- Lumos Insurance introduces the Immediate Care Plan to help families fund long-term care
More Annuity NewsHealth/Employee Benefits News
- Hinson unveils transparency bill amid scrutiny
- Genworth leans on mortgage unit, CareScout to offset Q2 LTC liabilities
- GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
- Govt Sets Ambitious Health Reform Agenda
- Humana Healthy Horizons in Indiana Collaborates with HealthStream to Expand and Strengthen Home Care Workforce
More Health/Employee Benefits NewsLife Insurance News
- Built to Last: Winston-Salem—a quiet industrial powerhouse
- The silver economy ushers in a new era of life insurance growth
- Family communication: Financial planning’s growing blind spot
- Indiana eyes more oversight of insurance companies' exposure to private credit
- HEALEY-DRISCOLL ADMINISTRATION RETURNS $14.5 MILLION TO HEALTH AND DENTAL INSURANCE CONSUMERS AND BUSINESSES
More Life Insurance News